GjertsonD.W.Survival trends in long-term first cadaver-donor kidney transplants. Clin Transpl1991: 225–35.
2.
AugustineJ.J., BodziakK.A., HricikD.E.Use of sirolimus in solid organ transplantationDrugs2007; 67: 369–91.
3.
MacDonaldA.S.Use of mTOR inhibitors in human organ transplantation. Exper Rev Clin Immunol2007; 3: 423–36.
4.
SchuurmannH.J., RingersJ., SchulerW.. Oral efficacy of the macrolide immunosuppressant SDZ-RAD and of cyclosporine microemulsion in cynomolgus monkey kidney transplantation. Transplantation2000; 69: 737–42.
5.
ColeO.J., ShehataM., RiggK.M.Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model. Transplant Proc1998; 30: 2200–03.
6.
KovarikJ.M., BeyerD., SchmouderR.L.Everolimus drug interactions: application of a classification system for clinical decision making. Biopharm Drug Dispos2006; 27: 421–6.
7.
VitkoS., MargreiterR., WeimarW.. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant2005; 5(10): 2521–30.
8.
LorberM.I., MulgaonkarS., ButtK.M.. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation2005; 80(2): 244–52.
9.
NashanB., CurtisJ., PonticelliC., MouradG., JaffeJ., HaasT.; 156 Study Group. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open label study. Transplantation2004; 78: 1332–40.
10.
VitkoS., TedescoH., ErisJ.. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant2004; 4(4): 626–35.
11.
SalvadoriM., ScolariM.P., BertoniE.. Everolimus with very low-exposure Cyclosporine A in de novo kidney transplantation: a multicenter, randomized, controlled trial. Transplantation2009; 88(10): 1194–202.
12.
BuddeK., BeckerT., ArnsW.. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet2011 epub ahead of prints.
13.
Catania-DavilaA., Zuniga-VargaJ., Correa-RotterR.. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination. Transplant Proc2009; 41: 4138–46.
14.
SchenaF.P., PascoeM.D., AlberuJ.. Sirolimus CONVERT Trial Study Group. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety from the CONVERT trial. Transplantation2009; 87: 233–42.
15.
ValantineH.Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology. J Heart Lung Transplant2007; 26: 557–64.
16.
FishmanJ.A., EmeryV., FreemanR.. Cytomegalovirus in transplantation- challenging the status quo. Clin Transplant2007; 21: 149–58.
17.
CampistolJ.M., ErisJ., OberbauerR.. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol2006; 17(2): 581–9.
18.
MotzerR.J., EscudierB., OudardS.. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet2008; 372: 449–56.
BertoniE., LartiA., RossoG., ZanazziM., Di MariaL., SalvadoriM.Good outcomes with Cyclosporine very low exposure with everolimus high exposure in renal transplant patients. J Nephrol2011, epub ahead of prints.
21.
StalloneG., Di PaoloS., SchenaA.. Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1-year graft function. J Am Soc Nephrol2004; 15(1): 228–s33.
